BioSpace News Archive

Conference Call and Webcast Scheduled for Thursday, March 18, 2021 at 8:30 AM ET

KIYATEC, Inc. today announced that research published in the March 2021 Cancer Immunology, Immunotherapy journal solidifies the foundation to characterize predictive accuracy in immuno-oncology.

ITOCO INC. is pleased to announce that it has signed a purchase agreement with ECAPFIN S.A.P.I. De C.V. of Domicilio DISTRITO FEDERAL Mexico, to acquire all the assets of the company which include:.

NEOTENY, a chemical company specializing in film making, announced that it has received ISO 21702 certification from an antiviral testing agency in France, confirming that its antiviral film ACLIV can kill COVID-19 virus by 99.9% within 30 minutes.

Annual survey results reveal company receives top ranking in community setting for the fifth consecutive year

Delonix Bioworks Ltd., a biotechnology company dedicated to developing the next generation vaccines with synthetic biology approaches, has recently closed a $14 million Series Seed financing led by Boehringer Ingelheim Venture Fund and IDG Capital, with participation from ZhenFund and an undisclosed investor.

Avinger, Inc. (Nasdaq: AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that Mark Weinswig, CFO, will be attending the Q1 Virtual Investor Summit.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2020.

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II).

- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call on March 18